NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 67 filers reported holding NURIX THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $14,621,000 | -44.2% | 1,154,000 | -38.3% | 0.31% | -23.7% |
Q1 2022 | $26,199,000 | -51.6% | 1,870,000 | 0.0% | 0.41% | -40.8% |
Q4 2021 | $54,137,000 | +50.6% | 1,870,000 | +55.8% | 0.69% | +46.0% |
Q3 2021 | $35,952,000 | +12.9% | 1,200,000 | 0.0% | 0.47% | +10.7% |
Q2 2021 | $31,836,000 | -14.7% | 1,200,000 | 0.0% | 0.43% | -22.6% |
Q1 2021 | $37,308,000 | +8.1% | 1,200,000 | +14.3% | 0.55% | +4.5% |
Q4 2020 | $34,524,000 | +98.7% | 1,050,000 | +111.0% | 0.53% | +55.6% |
Q3 2020 | $17,376,000 | – | 497,740 | – | 0.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ponoi II Management, LLC | 327,123 | $4,583,000 | 10.17% |
TRV GP III, LLC | 1,922,549 | $26,935,000 | 7.31% |
Ponoi Management, LLC | 327,122 | $4,583,000 | 5.95% |
Foresite Capital Management IV, LLC | 1,030,798 | $14,441,000 | 4.04% |
DAFNA Capital Management LLC | 543,344 | $7,612,000 | 1.98% |
Soleus Capital Management, L.P. | 1,011,638 | $14,173,000 | 1.83% |
Bain Capital Life Sciences Investors, LLC | 1,284,313 | $17,993,000 | 1.75% |
Redmile Group, LLC | 3,018,784 | $42,293,000 | 1.32% |
WestHill Financial Advisors, Inc. | 283,333 | $3,969,000 | 1.14% |
Boxer Capital, LLC | 1,224,892 | $17,161,000 | 0.88% |